Otsuka's ADHD approval opens up new drug class with $615M opportunity

Otsuka's centanafadine (Simtriyo) becomes the first norepinephrine-dopamine-serotonin reuptake inhibitor approved for ADHD, with peak sales forecast at $615m. The drug launches later this year pending DEA scheduling and carries boxed warnings for suicidal ideation and abuse potential.

This Wire brief sits within Fusion42's coverage of Drug Discovery. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.